Novartis to submit revised filing package for re-examination with request for conditional approval following CHMP negative opinion RLX030 is currently the only drug for which a reduction in mortality ...
Basel, January 24, 2014 - Novartis announced today it will shortly submit a revised filing package, including new data analyses, for re-examination for conditional approval of RLX030 (serelaxin) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results